ManageChatDiscover
122966

Synergistic and chemosensitizing effects of bovine lactoferrin or muramyl dipeptide in Ehrlich solid tumor-bearing mice treated with cisplatin

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Anti-cancer Immunotherapy
Cellular and molecular targeting
Inflammatory and cancer
Natural/synthetic agents in anti-cancer therapy

Abstract

Background: Despite the effectiveness of anti-cancer chemotherapy, it is associated with serious adverse side effects and the development of drug-resistance mechanisms. Immune dysfunction is considered one of the most serious adverse effects of anti-cancer chemotherapy, which increases the susceptibility of the patients to infection. Co-administration of immunomodulatory agents as adjuvant therapy with chemotherapy will result in better anti-tumor responses with fewer side effects. Aim: This study was designed to evaluate the ameliorative effects of bovine lactoferrin (bLF) and muramyl dipeptide (MDP) against toxicity induced by cisplatin in tumor-bearing mice. Materials and Methods: In this study, MDP or bLF was co-treated with cisplatin in mice bearing Ehrlich solid tumor (EST). Results: Co- treatment of cisplatin with MDP or bLF enhanced the anti-tumor effects of cisplatin to induce a reduction of the tumor size, proliferative capabilities of tumor cells accompanied by an elevation in the apoptotic profile of tumor cells. Moreover, co- treatments of Cisplatin with bLF or MDP reversed the Cisplatin-induced immune suppression and partially restored splenocyte proliferation, immune organ indices, hematological profile, liver and kidney functions, and histological structure. Conclusion: Both bLF and MDP were able to act as adjuvant therapy with anti-cancer chemotherapy through their abilities to enhance the chemotherapy curative effects, modulate the immune response against tumor cells, and to some extent ameliorate the adverse toxic effects of the chemotherapy.

DOI

10.21608/jcbr.2020.32770.1047

Keywords

Cisplatin, Immunohistochemistry, immunosuppression, Lactoferrin, Muramyl dipeptide

Authors

First Name

Dalia

Last Name

Morsi

MiddleName

-

Affiliation

Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt

Email

daliasami46@yahoo.com

City

Shibin al Kom

Orcid

-

First Name

Mohamed

Last Name

Salem

MiddleName

Labib

Affiliation

Immunology and Biotechnology Division, Department of Zoology, Faculty of Science, Tanta University, Egypt

Email

mohamed.labib@science.tanta.edu.eg

City

Egypt

Orcid

0000-0001-9454-6327

First Name

Hany

Last Name

Ibrahim

MiddleName

-

Affiliation

Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt

Email

hanyibrahimeg@gmail.com

City

-

Orcid

-

First Name

Gamalat

Last Name

Osman

MiddleName

-

Affiliation

Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt

Email

dr.gyosman@yahoo.com

City

-

Orcid

-

First Name

Azza

Last Name

Mohamed

MiddleName

-

Affiliation

Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt

Email

azza_hassan_2006@yahoo.com

City

-

Orcid

0000-0002-0770-7194

First Name

Amany

Last Name

Nofal

MiddleName

-

Affiliation

Zoology Department, Faculty of Science, Menoufia University, Shibin El-Kom, Egypt

Email

anofal@list.ru

City

-

Orcid

-

Volume

5

Article Issue

1

Related Issue

23533

Issue Date

2021-03-01

Receive Date

2020-06-15

Publish Date

2021-03-01

Page Start

75

Page End

94

Print ISSN

2682-261X

Online ISSN

2682-2628

Article File

JCBR_Volume 5_Issue 1_Pages 75-94.pdf

PDF . 10.8MB

Link

https://jcbr.journals.ekb.eg/article_122966.html

Detail API

https://jcbr.journals.ekb.eg/service?article_code=122966

Order

8

Type

Original Article

Type Code

885

Publication Type

Journal

Publication Title

International Journal of Cancer and Biomedical Research

Publication Link

https://jcbr.journals.ekb.eg/

MainTitle

Synergistic and chemosensitizing effects of bovine lactoferrin or muramyl dipeptide in Ehrlich solid tumor-bearing mice treated with cisplatin

Details

Type

Article

Created At

22 Jan 2023